The insider sales are small relative to market cap and follow a large equity grant cycle, making them consistent with routine tax-planning or diversification. The historical track record of insider BUYS at ARTV has been strongly predictive of upside (100% win rate at T+20), but this cluster is entirely sells. Monitor for any upcoming pipeline catalysts (clinical data readouts, regulatory updates) that could explain the timing, but do not read this cluster as a bearish signal on its own.
Price Chart
Executive Summary
Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over a one-week window. These sales follow a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven (tax planning, diversification) rather than signaling a bearish view on the company's pipeline. The total dollar value is ~0.1% of the $500M market cap, falling at the low end of the trivial-to-modest range, and the historical pattern of insider buys at this company has been strongly predictive of upside, not sales. The cross-filing context shows no bearish corporate events (no earnings miss, no restructuring, no late filing) that would amplify the signal, and the actuarial verdicts confirm that insider-sale clusters without such context are not amplified. The net impact is neutral to slightly cautious, but not a material sell signal.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 23.4K shares for ~$256K on 2026-09-08 at $10.92/share.
- COO Jennifer Bush sold 8.4K shares for ~$94K on 2026-09-03 at $11.16/share.
- CTO Christopher Horan sold 10.4K shares for ~$116K on 2026-09-03 at $11.16/share.
- CMO Subhashis Banerjee sold 1.1K shares for ~$12K on 2026-09-03 at $11.16/share.
- Total open-market sales of ~$477K represent ~0.1% of the $500M market cap — trivial by proportionality standards.
- All four executives received large non-cash equity grants (totaling ~856K shares) in the same week, consistent with a standard equity compensation cycle.
Financial Impact
Total insider sales of ~$477K, or ~0.1% of market cap — immaterial from a capital markets perspective.
Risk Factors
- Insider sales could accelerate if the stock rallies, creating overhead supply.
- No open-market insider buying in the cluster — absence of bullish insider conviction.
- Clinical-stage biotech risk: any pipeline setback could amplify the modest insider selling pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789432300198 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access